Zusammenfassung
Die Psoriasisarthritis (PsA) ist in den zurückliegenden Jahren zunehmend in den Fokus der klinischen Forschung gerückt. Dies betrifft klinische Langzeitregister, Studien zur Epidemiologie, Genetik und namentlich zur Therapie. Die Methodologie der Messung von Krankheitsaktivität, -schaden und -progression, die Dokumentation der Veränderung dieser Parameter im Krankheitsverlauf und die daraus resultierenden Definitionen von Zielkriterien einer Therapie sind allerdings bei der PsA weit weniger gut entwickelt als beispielsweise bei der rheumatoiden Arthritis (RA). In Studien zur PsA kommen häufig Outcome-Parameter zur Anwendung, die aus Studien zur RA, zur ankylosierenden Spondylitis oder der Psoriasis abgeleitet wurden und nicht für die PsA evaluiert wurden. Die vorliegende Arbeitet gibt eine Übersicht über allgemeine rheumatologische und PsA-spezifische Messinstrumente, Outcome-Parameter und Zielkriterien der Therapie bei PsA.
Abstract
Psoriatic arthritis (PsA) has increasingly attracted the attention of clinical research in recent years with regard to long-term clinical registries, studies on epidemiology, genetics, and therapy. However, the methodology for assessing disease activity, damage and progression, as well as the resulting definition of treatment outcome parameters have progressed far less in PsA as compared to other rheumatic diseases such as rheumatoid arthritis (RA). Most of the assessment methodologies have been adapted from clinical trials on RA, ankylosing spondylitis, or psoriasis, but have not yet been validated for use in PsA. This article gives an overview of general rheumatological and PsA-specific assessment methods and outcome parameters of PsA therapy.
Literatur
Antoni CE, Kavanaugh A, Kirkham B et al (2005) Sustained benefits of Infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis. Arthritis Rheum 52:1227–1236
Chandran V, Schentag CT, Gladman DD (2007) Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 57:1560–1563
Clegg DO, Reda DJ, Mejias E et al (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of veterans affairs cooperative study. Arthritis Rheum 39:2013–2020
Felson DT, Anderson JJ, Boers M et al (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727–735
Fredriksson T, Pettersson U (1978) Severe psoriasis: oral therapy with a new retinoid. Dermatologica 157:238–244
Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210–216
Gladman DD, Farewell VT, Wong K, Husted J (1998) Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 41:1103–1110
Gladman DD, Helliwell P, Mease PJ et al (2004) Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 50:24–35
Gladman DD, Antoni C, Mease P et al (2005) Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis 64 (Suppl II):ii14–ii17
Gladman DD, Mease PJ, Healy P et al (2007) Outcome measures in psoriatic arthritis. J Rheumatol 34:1159–1166
Gladman DD, Mease PJ, Strand V et al (2007) Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 34:1167–1170
Helliwell PS, Firth J, Ibrahim GH et al (2005) Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 32:1745–1750
Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A et al (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62:127–132
International Multi-centre Psoriasis and Psoriatic Arthritis Reliability Trial (GRAPPA-IMPART) (2007) Assessment of skin, joints, nails and dactylitis. Toronto, Canada
Jacobson CC, Kimball AB (2004) Rethinking the psoriasis area and severity index: the impact of area should be increased. Br J Dermatol 151:381–387
Lynch M, Ng CT, Saber TP, Grier A et al (2008) The 28 Joint count underestimates extent of disease in Psoriatic arthritis. Arthritis Rheum 58 (Suppl):363
Mander M, Simpson JM, McLellan A et al (1987) Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 46:197–202
Mease PJ, Goffe BS, Metz J et al (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385–390
Mease PJ, Antoni CE, Gladman DD, Taylor WJ (2005) Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 64 (Suppl II):ii49–ii54
Moll JMH, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3:51–78
Nell Duxneuner P, Stamm T, Aletaha D et al (2007) Measures associated with disease activity in psoriatic arthritis. Arthritis Rheum 56 (Suppl):481
Ritchlin CT, Kavanaugh A, Gladman D et al (2008) Treatment recommendation for psoriatic arthritis. Arthritis Rheum 58 (Suppl):363–364
Taylor WJ, Zmierczak HG, Helliwell PS (2005) Problems with the definition of axial and peripheral disease patterns in psoriatic arthritis. J Rheumatol 32:974–977
Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673
van der Heijde DM, van’t Hof MA, van Riel PL et al (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49:916–920
van der Heijde D (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27:261–263
van der Heijde D, Sharp J, Wassenberg S, Gladman DD (2005) Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 64:ii61–ii64
van Gestel AM, Prevoo ML, van’t Hof MA et al (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39:34–40
Wassenberg S, Fischer-Kahle V, Herborn G, Rau R (2001) A method to score radiographic change in psoriatic arthritis. Z Rheumatol 60:156–166
Interessenkonflikt
Die korrespondierende Autorin weist auf folgende Beziehungen hin: Referententätigkeit für die Firmen Abbott Immunology, Essex, Wyeth.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Märker-Hermann, E., Behrens, F. Psoriasisarthritis. Z. Rheumatol. 68, 16–22 (2009). https://doi.org/10.1007/s00393-008-0360-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-008-0360-z